A federal watchdog weighed in Tuesday on the Food and Drug Administration’s controversial accelerated approval pathway, identifying three instances where the FDA deviated from protocol during a ...
The Health and Human Services Office of Inspector General has found that, in a few cases, FDA officials veered from the accelerated approval pathway.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback